On 26 September, Synaptogenix, a clinical-stage biopharmaceutical company developing therapeutics for neurodegenerative disorders, announced a peer-reviewed publication of data from its Phase II trial of Bryostatin-1 for Alzheimer's disease (AD) in the Journal of Alzheimer's Disease. The Phase II trial was a 6-month randomised, double-blind and placebo-controlled study comparing Bryostatin-1 to placebo for long-term efficacy in the treatment of advanced and severe AD in the absence of memantine. A total of 221 participants were enrolled in the study. The overall treatment emergent adverse event profile was similar between the placebo and Bryostatin-1 groups. Findings showed that six months of treatment with Bryostatin-1 slowed cognitive decline in participants from the moderate group (MMSE 10-14) compared to placebo group. This effect was maintained four months after stopping treatment.
https://content.iospress.com/articles/journal-of-alzheimers-disease/jad…